Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 28, 2011; 17(8): 1045-1050
Published online Feb 28, 2011. doi: 10.3748/wjg.v17.i8.1045
Published online Feb 28, 2011. doi: 10.3748/wjg.v17.i8.1045
Table 1 Tumor size
| Pre-treatment | Post-treatment | Ratio | |
| Sorafenib 1 | 69.4 | 159.0 | 2.3 |
| Sorafenib 2 | 58.6 | 165.3 | 2.8 |
| Sorafenib 3 | 109.0 | 150.9 | 1.4 |
| Sorafenib 4 | 192.9 | 547.2 | 2.8 |
| Control 1 | 49.0 | 210.3 | 4.3 |
| Control 2 | 24.5 | 240.0 | 9.8 |
| Control 3 | 78.8 | 246.1 | 3.1 |
| Control 4 | 30.6 | 436.6 | 14.0 |
- Citation: Yoshida K, Hirokawa T, Moriyasu F, Liu L, Liu GJ, Yamada M, Imai Y. Arterial-phase contrast-enhanced ultrasonography for evaluating anti-angiogenesis treatment: A pilot study. World J Gastroenterol 2011; 17(8): 1045-1050
- URL: https://www.wjgnet.com/1007-9327/full/v17/i8/1045.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i8.1045